Synbiotic Se
Synbiotic SE is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of rare diseases, particularly in the field of hematology and oncology.
Business. SYNBIOTIC SE is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product-based revenue models typical of the industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Xetra exchange under the ticker symbol SBXN.DE.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SYNBIOTIC SE is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product-based revenue models typical of the industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Xetra exchange under the ticker symbol SBXN.DE.
Synbiotic's capital structure is characterized by a lack of detailed liquidity metrics, as the company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company has no dilution risk in the near term, with both basic and diluted shares outstanding being equal at 7,456,954 shares.
Profitability and returns data are not available for Synbiotic, as the valuation snapshot does not provide metrics such as ROIC or margins. Without these metrics, it is not possible to compare the company's performance against industry_config preferred metrics or cohort medians.
Synbiotic's revenue concentration and geographic exposure are not disclosed in the available data. The company's business is primarily focused on the development and commercialization of therapies for rare diseases, but specific segments or geographic regions contributing to revenue are not provided.
The company's growth trajectory is not quantified in the available data. No numeric deltas or revenue history are provided to assess the current or next fiscal year's direction.
Risk factors for Synbiotic include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. The company has a low dilution potential, as there is no difference between basic and diluted shares outstanding.
Recent events and filings for Synbiotic are not detailed in the available data. No specific filings or transcripts are provided to inform on recent company developments.
- Synbiotic operates in the pharmaceuticals industry with a focus on rare disease therapies.
- The company's liquidity risk could not be assessed due to missing balance-sheet data.
- There is no dilution risk in the near term, as basic and diluted shares are equal.
- Profitability and returns metrics are not available for comparison with industry benchmarks.
- Revenue concentration and geographic exposure details are not disclosed.
- Analysts have a neutral to positive outlook, with a mean recommendation of 1.50 and a mean price target of 6.05 EUR.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €14.3M, +270,5% YoY; Operating income +9,9% YoY.
- ▍Revenue €14.3M, +270,5% YoY
- ▍Operating income +9,9% YoY
- ▍Net income +8,6% YoY
- ▍Free cash flow +4,9% YoY
- ▍Net margin -67.9%
Revenue €3.9M, −52,7% YoY; Operating income +54,7% YoY.
- ▍Revenue €3.9M, −52,7% YoY
- ▍Operating income +54,7% YoY
- ▍Net income +56,4% YoY
- ▍Free cash flow +57,2% YoY
- ▍Net margin -275.3%
Revenue €8.2M, −5,6% YoY; Operating income −125,5% YoY.
- ▍Revenue €8.2M, −5,6% YoY
- ▍Operating income −125,5% YoY
- ▍Net income −91,5% YoY
- ▍Free cash flow −96,0% YoY
- ▍Net margin -298.4%
Revenue €8.6M, +58,8% YoY; Operating income −1 278,4% YoY.
- ▍Revenue €8.6M, +58,8% YoY
- ▍Operating income −1 278,4% YoY
- ▍Net income −1 345,3% YoY
- ▍Free cash flow −337,9% YoY
- ▍Net margin -147.1%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,35 |
| Revenue | —no estimate | —no estimate | 16,4M EUR |
| Operating income | —no estimate | —no estimate | -2,2M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- SYNBIOTIC SE Market data — financials · 2026-05-29
- SYNBIOTIC SE Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Oliver ConradChairman of the Supervisory Board
- Sebastian StietzelChairman of the Supervisory Board